Cytokinetics Inc (CYTK)
Who owns Cytokinetics Inc (CYTK)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 91.2% of the shares are freely tradable; institutional investors hold 118.8%.
Ownership Structure
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| T. Rowe Price Investment Management,Inc. | 12.91 | 17,523,840 | -35.4 | 03/31/2026 |
| BlackRock Inc | 12.19 | 16,548,011 | +0.9 | 03/31/2026 |
| Vanguard Group Inc | 8.87 | 12,048,131 | +1.6 | 12/31/2025 |
| FMR Inc | 7.90 | 10,723,140 | -16.3 | 03/31/2026 |
| Wellington Management Company LLP | 5.90 | 8,009,489 | +0.9 | 03/31/2026 |
| Vanguard Portfolio Management, LLC | 4.30 | 5,843,782 | +0.0 | 03/31/2026 |
| State Street Corp | 4.23 | 5,745,193 | -1.4 | 03/31/2026 |
| Vanguard Capital Management, LLC | 4.04 | 5,488,634 | +0.0 | 03/31/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| T. Rowe Price Capital Appreciation | 3.76 | 5,105,689 | +0.0 | 04/30/2026 |
| iShares Core S&P Mid-Cap ETF | 3.30 | 4,482,210 | +0.0 | 05/29/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 30. Jul 2026 | Callos Andrew | EVP, Chief Commercial Officer | Sell | 14,000 | 79.88 | 1,118,320 |
| 30. Jul 2026 | Callos Andrew | EVP, Chief Commercial Officer | Other | 14,000 | 23.26 | 325,640 |
| 27. Jul 2026 | Blum Robert I | President & CEO | Sell | 7,500 | 80.87 | 606,525 |
| 27. Jul 2026 | Blum Robert I | President & CEO | Other | 7,500 | 10.60 | 79,500 |
| 21. Jul 2026 | Malik Fady Ibraham | EVP Research & Development | Sell | 3,500 | 80.59 | 282,065 |
| 21. Jul 2026 | Malik Fady Ibraham | EVP Research & Development | Other | 3,500 | 7.80 | 27,300 |
| 15. Jul 2026 | Wysenski Nancy | Director | Other | 75 | 82.62 | 6,197 |
| 15. Jul 2026 | Wierenga Wendell | Director | Other | 75 | 82.62 | 6,197 |
| 15. Jul 2026 | Kaye Edward M. MD | Director | Other | 151 | 82.62 | 12,476 |
| 15. Jul 2026 | Henderson John T | Director | Other | 272 | 82.62 | 22,473 |
| 15. Jul 2026 | Harrington Robert Arthur | Director | Other | 151 | 82.62 | 12,476 |
| 15. Jul 2026 | Daly James M | Director | Other | 151 | 82.62 | 12,476 |
| 13. Jul 2026 | Blum Robert I | President & CEO | Sell | 7,490 | 82.02 | 614,330 |
| 13. Jul 2026 | Blum Robert I | President & CEO | Other | 7,490 | 10.60 | 79,394 |
| 13. Jul 2026 | Blum Robert I | President & CEO | Sell | 10 | 82.02 | 820 |
| 21. Apr 2026 | Fady Ibraham Malik | EVP | Sell | 3,500 | 65.69 | 229,915 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
View all insider transactions →Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.